The first-in-class anti-EGFR antibody mixture Sym004 overcomes cetuximab resistance mediated by EGFR extracellular domain mutations in colorectal cancer

Clinical Cancer Research

Volumn 22, Issue 13, 2016, Pages 3260-3267

  Sánchez Martín, Francisco J ^a   Bellosillo, Beatriz ^b   Gelabert Baldrich, Mariona ^b   Dalmases, Alba ^b   Cañadas, Israel ^b   Vidal, Joana ^b   Martinez, Alejandro ^b   Argilés, Guillem ^c   Siravegna, Giulia ^d,e   Arena, Sabrina ^d,e   Koefoed, Klaus ^f   Visa, Laura ^b   Arpí, Oriol ^b   Horak, Ivan David ^f   Iglesias, Mar ^b   Stroh, Christopher ^g   Kragh, Michael ^f   Rovira, Ana ^b   Albanell, Joan ^b,h   Tabernero, Josep ^c   Bardelli, Alberto ^d,e   Montagut, Clara ^b   more..

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^d CANDIOLO CANCER INSTITUTE   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f Symphogen AS   (Denmark)

^g Merck Serono GmbH   (Germany)

^h UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FUTUXIMAB; PANITUMUMAB; EGFR PROTEIN, HUMAN; MONOCLONAL ANTIBODY; SYM004 ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER RESISTANCE; CELL VIABILITY; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SENSITIVITY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METASTATIC COLORECTAL CANCER; MOUSE; NONHUMAN; ONCOGENE K RAS; ONCOGENE N RAS; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR REGRESSION; TUMOR XENOGRAFT; 3T3 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL PROLIFERATION; COLORECTAL TUMOR; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; IMMUNOLOGY; MUTATION; PROCEDURES; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

3T3 CELLS; ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CELL PROLIFERATION; CETUXIMAB; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MICE; MICE, INBRED BALB C; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84964634075     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2400     Document Type: Article

References (21)

1. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
2. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369:1023-34.
3. Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med 2012;18:221-3.
4. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012;486:532-6.
5. Diaz LA, Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012;486:537-40.
6. Bardelli A, Corso S, Bertotti A, et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 2013;3:658-673.
7. Yonesaka K, Zejnullahu K, Okamoto I, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 2011;3:99ra86.
8. Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 2015;21:795-801.
9. Morelli MP, Overman MJ, Dasari A, Kazmi SM, Mazard T, Vilar E, et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol 2015;26:731-6.
10. Newhall K, Price T, Peeters M, Kim TW, Li J, Cascinu S, et al. Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from metastatic colorectal cancer patients treated with panitumumab or cetuximab monotherapy. Ann Oncol 2014;25:ii109.
11. Arena S, Bellosillo B, Siravegna G, Martinez A, Canadas I, Lazzari L, et al. Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. Clin Cancer Res 2015;21:2157-66.
12. Braig F, Marz M, Schieferdecker A, Schulte A, Voigt M, Stein A, et al. Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer. Oncotarget 2015;6:12035-47.
13. Siena S, Sartore-Bianchi A, Lonardi S, Trusolino L, Martino C, Bencardino K, et al. Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial. J Clin Oncol 33, 2015 (suppl; abstr 3508).
14. Misale S, Arena S, Lamba S, Siravegna G, Lallo A, Hobor S, et al. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med 2014;6:224ra26.
15. Voigt M, Braig F, Gothel M, Schulte A, Lamszus K, Bokemeyer C, et al. Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab. Neoplasia 2012;14:1023-31.
16. Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS, et al. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 2010;70:588-97.
17. Koefoed K, Steinaa L, Soderberg JN, Kjaer I, Jacobsen HJ, Meijer PJ, et al. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. MAbs 2011;3:584-95.
18. Iida M, Brand TM, Starr MM, Li C, Huppert EJ, Luthar N, et al. Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab. Neoplasia 2013;15:1196-206.
19. Dienstmann R, Patnaik A, Garcia-Carbonero R, Cervantes A, Benavent M, Rosello S, et al. Safety and activity of the first-in-class Sym004 anti-EGFR antibody mixture in patients with refractory colorectal cancer. Cancer Discov 2015;5:598-609.
20. Skartved NJ, Jacobsen HJ, Pedersen MW, Jensen PF, Sen JW, Jorgensen TK, et al. Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor. Clin Cancer Res 2011;17:5962-72.
21. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014;6:224ra24.